Boston Partners Long/Short Research Fd Inv Cl

The investment seeks long-term total return. The fund actively invests in long positions in stocks identified by the Adviser as undervalued and takes short positions in stocks that the Adviser has identified as overvalued. The cash proceeds from short sales (i.e. sales of securities the fund does not own) are invested in short-term cash instruments to produce a return on such proceeds just below the federal funds rate. The fund invests, both long and short, in equity securities issued by large-, mid- and small (or "micro") cap companies, as well as other instruments that are convertible into equity securities.

Boston Partners Long/Short Research Fd Inv Cl trades as BPRRX on NASDAQ. The company is classified in Financial Services / Asset Management - Leveraged and reports in USD.

The current profile places the business in Asset Management - Leveraged. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Latest available fiscal data shows $81.23M of revenue and $7.14M of net income.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

Boston Partners Long/Short Research Fd Inv Cl can be compared against peers such as American Century High-Yield Municipal Fund Investor Class, Alger Focus Equity Fund Class I, Boston Trust Asset Management Fund, Direxion Monthly NASDAQ-100 Bull 2X Fund Investor Class, Guggenheim Ultra Short Duration A, Matthews Asia Dividend Fund Investor Class.

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $588.06M, beta of 0.46, and return on equity of +1.4%.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

BPRRX currently shows total debt of $26.95M and beta of 0.46. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

Recent filings to review: 497 (2026-06-05 00:00:00), 485BXT (2026-06-04 00:00:00), 485BXT (2026-06-04 00:00:00), DEF 14A (2026-05-19 00:00:00).

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.bostonpartners.com/fund/bp-long-short-research-fund/

For US-listed stocks, verify the thesis against official filings, earnings call transcripts, and company investor relations materials.